Results

1–10 of 11 results for wet age-related macular degeneration

Vision Outcomes From the DAVIO 2 Trial: A Phase 2 Trial of EYP-1901 vs Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration
Jennifer I. Lim, MD, FARVO, FASRS
Annual Meeting Talks
2025
Treatment Burden in Wet Age-Related Macular Degeneration Treated With EYP-1901 vs Aflibercept in DAVIO 2, a Phase 2 Clinical Trial
Avni P Finn, MD, MBA, FASRS
Annual Meeting Talks
2025
Subgroup Analyses of the Phase 1 DAVIO Trial of EYP-1901 Showing Reduced Treatment Burden in Wet Age-related Macular Degeneration
Philip P Storey, MD, MPH
Annual Meeting Talks
2023
Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2024
Conversion Rates from Nonexudative to Exudative Age-Related Macular Degeneration: An AAO IRIS® Registry Analysis
Dan A Gong, MD
Annual Meeting Talks
2022
Demographic Variations in Response to Anti-VEGF in Treatment of Neovascular Wet Age-Related Macular Degeneration (nAMD) Patients: IRIS Registry Analysis
On Demand Cases, Courses, and Papers
2022
Lady in a dress
Shelby Helton
Thomas M. Aaberg Jr. , MD
Retina Image Bank: Images of the Week
2023
Cognitive Testing in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Wet Age-Related Macular Degeneration
Subhransu K. Ray, MD, PhD
Annual Meeting Talks
2020
Intravitreal AAVCAGsCD59 as Adjunct Anti-VEGF Treatment for Wet Age-Related Macular Degeneration
Jeffrey S. Heier, MD
Annual Meeting Talks
2020
One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Mark R. Barakat, MD
Updates from the Field
2020